tailieunhanh - Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: Results from a crosssectional study

Clinical studies demonstrate that ivacaftor (IVA) improves health-related quality of life (HRQoL) in patients aged ≥6 years with cystic fibrosis (CF). The real-world impact of IVA and standard of care (SOC) in groups of patients with G551D and F508del mutations, respectively, was assessed using a survey comprising disease-specific and generic HRQoL measures. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN